Skip to search formSkip to main contentSkip to account menu

beclabuvir

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Effect of CYP3A5*3 genetic variant on the metabolism of direct-acting antivirals in vitro: a different effect on asunaprevir versus daclatasvir and beclabuvir
Direct-acting antivirals, asunaprevir (ASV), daclatasvir (DCV), and beclabuvir (BCV) are known to be mainly metabolized by CYP3A… 
2018
2018
Pooled Analysis of HCV Genotype 1 Resistance-Associated Substitutions in NS5A, NS3 and NS5B pre- and Post-Treatment with 12 Weeks of Daclatasvir, Asunaprevir and Beclabuvir
Background Daclatasvir (DCV; non-structural [NS]5A inhibitor) plus asunaprevir (ASV; NS3 inhibitor) plus beclabuvir (BCV; non… 
2018
2018
Safety Exposure‐Response Analysis for Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV‐Infected Subjects
The combination regimen of daclatasvir, asunaprevir, and beclabuvir has been developed for the treatment of hepatitis C virus… 
2018
2018
Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of…
BackgroundIn the UNITY-3 study, 96% sustained virologic response (SVR12) rate was observed in Japanese patients with hepatitis C… 
2018
2018
Natural polymorphisms in the resistance associated sites of HCV-G1 NS5B domain and correlation with geographic origin of HCV isolates
We evaluated the frequency of naturally occurring resistance associated substitutions (RASs) and their characteristic of… 
2017
2017
Daclatasvir/asunaprevir/beclabuvir, all‐oral, fixed‐dose combination for patients with chronic hepatitis C virus genotype 1
This multinational (Taiwan, South Korea, Russia) phase 3 study evaluated the all‐oral, ribavirin‐free, fixed‐dose combination… 
Review
2017
Review
2017
The safety and efficacy of the combination daclatasvir, asunaprevir and beclabuvir in the treatment of chronic hepatitis C virus: a systematic review and meta-analysis
Review
2016
Review
2016
Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection
The treatment of chronic hepatitis C is revolutionizing rapidly. The aim of this study is to review the efficacy and safety of… 
2015
2015
Continued progress against hepatitis C infection.
  • H. Conjeevaram
  • Journal of the American Medical Association (JAMA…
  • 2015
  • Corpus ID: 11699062
The worldwide epidemic of hepatitis C virus (HCV) infection affects more than 130 million people,1 includes healthrelatedoutcomes… 
2015
2015
Updates on the Pharmacology of Antiretrovirals and DAAs
17. 7. Zeuzem S, Ghalib R, Rajender Reddy K, et al. Grazoprevir–elbasvir combination therapy for treatmentnaive cirrhotic and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)